期刊
NATURE MEDICINE
卷 25, 期 5, 页码 751-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-019-0424-4
关键词
-
资金
- European Union [306125]
- ARC Foundation for Cancer Research (France)
- Lilly France SAS
- Novartis Pharmaceuticals Corporation
- Pfizer Oncology
- Fero/J.P. Morgan Private Bank Clinical Oncology Research Grant
- National Cancer Institute [P30 P30-CA023100]
- Israeli Science Foundation [1188/16]
- Instituto Salud Carlos III-Programa Rio Hortega Contract grant [CM15/00255]
- Canadian Institutes for Health Research [MOP-142281]
- Canadian Cancer Society [703811]
Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial (NCT01856296) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease >= 6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P < 0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据